Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Kidney Int. 2017 Dec 19;93(4):842–854. doi: 10.1016/j.kint.2017.09.029

Figure 5. Systemic administration of ELP-VEGF attenuated renal apoptosis and fibrosis in the stenotic kidney.

Figure 5

Representative stenotic kidney pictures (x40), showed as examples to illustrate and quantify the fraction of apoptotic cells (TUNEL, A) and fibrosis (trichrome, B) in the stenotic kidney after ELP-VEGF therapy or placebo. * p<0.05 vs. Normal; † p<0.05 vs. RVD.